Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Simmons, G.
Right arrow Articles by Calder, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simmons, G.
Right arrow Articles by Calder, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 909-911
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria meningitidis

Greg Simmons*, Nicholas Jones and Lester Calder

Auckland Healthcare Public Health Protection, Auckland, New Zealand

The efficacy of ceftriaxone in eliminating nasopharyngeal carriage of Neisseria meningitidis was compared with that of rifampicin during an epidemic of serogroup B meningococcal disease in Auckland, New Zealand. Household contacts of cases had a throat swab taken and were randomized to treatment. Carriers had a repeat swab taken 6 days later to determine efficacy of treatment. Ceftriaxone (98.2%) was equivalent to rifampicin (97.6%) in eliminating serogroup B N. meningitidis. It is cheaper than rifampicin and has the advantage of full compliance and fewer contraindications, but its acceptability by patients may limit its use as a first-line prophylactic agent.

* Correspondence address. Auckland Healthcare Services Ltd, Private Bag 92605, Symonds Street, Auckland 1, New Zealand. Tel: +64-9-623-4613; Fax: +64-9-630-7431; E-mail: gregs{at}ahsl.co.nz


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
J. Tapsall, P. Read, C. Carmody, C. Bourne, S. Ray, A. Limnios, T. Sloots, and D. Whiley
Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods
J. Med. Microbiol., May 1, 2009; 58(5): 683 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
L. H. Harrison
Prospects for Vaccine Prevention of Meningococcal Infection
Clin. Microbiol. Rev., January 1, 2006; 19(1): 142 - 164.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
S. P. Yazdankhah and D. A. Caugant
Neisseria meningitidis: an overview of the carriage state
J. Med. Microbiol., September 1, 2004; 53(9): 821 - 832.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.